Sep 23, 2025 · 58m · a16z
Taking Bold Bets: NIH and the Future of Biomedical Science
Dr. Jay Bhattacharya · 39m spoken Vineeta Agarwala · 8m spoken Jorge Conde · 3m spoken Erik Torenberg · 1m spoken
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of The a16z Podcast, NIH Director Dr. Jay Bhattacharya outlines reforms to rebuild public trust, address the scientific replication crisis, adopt venture-capital-style grant funding, and empower early-career researchers to combat stagnating U.S. life expectancy.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The host holds 2.7% of the talking time here. How this is scored →
The host as informed peer 3.9 Guest teaching 5.3 Guest disagreement 1.6 The host pushing back 1.6
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 18:52 Rejecting technocratic allocation by scientific 'philosopher kings'
Dr. Bhattacharya forcefully rejects Vineeta's suggestion that scientific experts alone should allocate research funds, insisting that democracy demands public political input and rejecting the notion of expert 'philosopher kings'.
Hardest push from the host ▶ 17:56 Vineeta challenges political budget allocation over expert guidanceVineeta explicitly states 'let me push back on that' and argues that the public intentionally offloads cognitive load to biomedical experts rather than wanting political input on disease funding.
Biggest teaching moment ▶ 48:00 Citing MMR versus COVID booster uptake to defend public discernmentDr. Bhattacharya educates the hosts on public intelligence by contrasting the 95% uptake rate of MMR vaccines with the 13% uptake rate of COVID boosters, showing how citizens logically weigh scientific evidence.
The host holds their own ▶ 14:25 Vineeta's capital allocation versus operational execution frameworkVineeta demonstrates sharp institutional expertise by breaking down the $35B+ NIH budget into a precise microeconomic framework of portfolio capital allocation versus operational execution, earning praise from the guest.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Autism Research Funding and Maternal Health Guidelines | 2 | 4 | 1 | 1 | Dr. Bhattacharya introduces new NIH initiatives on autism, Leucovorin, and Tylenol pregnancy guidance. The host asks a straightforward clarifying question regarding updated guidelines, keeping the dynamic informative and collaborative. | |
| Preterm Birth Research and Scientific Replication Standards | 3 | 5 | 1 | 1 | Vineeta Agarwala highlights preterm birth research as an adjacent priority. Dr. Bhattacharya expands on scientific replication standards and the necessity of independent verification over authority. | |
| Structural Causes of the Scientific Replication Crisis | 2 | 6 | 1 | 0 | The host asks an open question about why scientific replication has suffered. Dr. Bhattacharya educates the hosts on structural publication incentives, extreme specialization, and the 20-year replication crisis. | |
| Mid-Term Reflections on Directing the NIH | 3 | 5 | 1 | 1 | Dr. Bhattacharya reflects on centralizing grant reviews and applying a Silicon Valley venture portfolio model to scientific risk. The host asks a targeted follow-up on whether grant mechanisms or scientists themselves became overly cautious. | |
| Strategic Capital Allocation versus Operational Execution at NIH | 8 | 6 | 4 | 8 | Vineeta Agarwala presents a sophisticated microeconomic framework splitting NIH duty into capital allocation versus operational execution, then explicitly pushes back against public involvement in allocation. Dr. Bhattacharya firmly counters that technocratic scientist control fails to reflect public will, citing historical HIV patient activism. | |
| Aligning Research Priorities with Stagnant Life Expectancy | 2 | 5 | 1 | 0 | Erik Torenberg prompts Dr. Bhattacharya on misallocated research sectors. Dr. Bhattacharya details stagnant US life expectancy and advocates reallocating resources toward rampant chronic health conditions. | |
| Empowering Early-Career Researchers and Young Scientists | 5 | 5 | 1 | 1 | The host draws a venture capital analogy regarding LP oversight and aging awardee demographics. Dr. Bhattacharya cites data showing the median first-grant age rising to mid-40s and outlines structural reforms to empower young investigators. | |
| Addressing Bottlenecks in Academic Research Career Pipelines | 6 | 5 | 1 | 2 | Vineeta Agarwala draws on her NIH MSTP MD-PhD background to question university career continuity for young researchers. Dr. Bhattacharya explains the specific structural bottleneck when transitioning from postdocs to assistant professorships. | |
| Chronic Disease Demands and Public Calls for Reform | 5 | 5 | 2 | 1 | Vineeta brings up academic publishing monopolies and high open-access fees. Dr. Bhattacharya outlines NIH policy changes ending internal publication permissions and removing reader paywalls for publicly funded research. | |
| Restoring Public Trust Through Transparency and Humility | 3 | 6 | 3 | 1 | The host asks how public health trust can be restored post-pandemic. Dr. Bhattacharya criticizes unscientific pandemic measures and uses a third-year medical student white coat metaphor to argue for humility when facing uncertainty. | |
| Communicating Scientific Certainty versus Respecting Public Intelligence | 6 | 6 | 3 | 5 | Vineeta challenges Dr. Bhattacharya on how to communicate scientific certainty without undermining trust in established vaccines like Hep B. Dr. Bhattacharya reframes the issue by pointing to 95% MMR uptake versus 13% COVID booster uptake to argue that the public accurately weighs data. | |
| Emerging Breakthroughs in Alzheimer Research and AI Integration | 2 | 6 | 1 | 0 | Erik Torenberg inquires about AI integration and chronic disease priorities. Dr. Bhattacharya details Zostavax repurposing research for Alzheimer prevention and highlights AlphaFold computations and administrative AI scribes. | |
| Differentiating AI Capability from Human Scientific Creativity | 4 | 6 | 2 | 2 | Vineeta playfully asks if AI will take over scientific roadmap writing and grant reviews. Dr. Bhattacharya firmly rejects this, framing AI as an efficiency tool and sharing Max Perutz's decade-long struggle with myoglobin structure to illustrate human scientific creativity. | |
| Diversified Portfolio Strategies and Podcast Conclusion | 3 | 4 | 1 | 0 | The host asks whether health gains will stem from disease management, novel molecules, or lifestyle changes. Dr. Bhattacharya advocates for a diversified portfolio across all three, citing GLP-1 developments before closing. |
Statements from this episode (36)
Bhattacharya: Public will trust science if shown transparent data and evidence
“When we talk to them in ways where we show respect for their intelligence with data, allow people to disagree, but then have the evidence right there in front of people, I think people, people will respond with trust where the evidence actually leads.”
NIH awards $50M to 13 research teams for Autism Data Science Initiative
“Fifty million new dollars. 250 teams applied for large research grants, and we're gonna announce today that 13 teams are going to be granted you know, these grants this, for this Autism Data Science Initiative.”
Bhattacharya: Leucovorin restores speech in 20% of autistic kids with folate deficiency
“You know, for kids who have this folate deficiency in their brains, that, it actually works. And 20% of the kids, I think, restore speech. Up to 60% of the kids, they get much better.”
Bhattacharya: FDA will issue updated pregnancy guidelines for acetaminophen use
“There will be, yeah. So that's something that Dr. McCary, the FDA commissioner is working on. And there'll be also you know, changes in, in like how Medicare pays, Medicare, CMS, Medicare, and Medicaid pay for Leucovorin. So it's a cross-agency collaboration f…”
Bhattacharya: US has worse preterm birth outcomes than Europe
“Like, we have worse outcomes in the United States than Europe does.”
Bhattacharya: Replication ought to be the standard for truth in science
“The standard for truth in science ought to be replication.”
Bhattacharya: Academic incentives fail to reward checking other scientists' work
“There's no return for it. Like, if I spend my career checking other people's work, I'm not going to get a professorship at a fancy university.”
Bhattacharya: Peer-reviewed journal publication does not equal scientific truth
“The fact that it's published in a journal doesn't mean it's right. It doesn't mean it's true.”
Bhattacharya: NIH funded the Wuhan lab without the capability to audit it
“The NIH had sent money to the Wuhan lab but we couldn't audit it.”
Bhattacharya: NIH shifted from funding fresh ideas to older research projects
“Look, if you look at back in the 19 eighties and 19 nineties, the NIH was funding ideas that were like zero, one, two years old. The typical scientific project funded by the NIH in the 2000 teens, it was about 2002 thousand, early 2002 thousand teens was like …”
Bhattacharya: Science needs Silicon Valley spirit to destigmatize productive failure
“We should stop punishing scientists who fail. If they fail productively, let them publish in a journal to explain why they're, what they learned from it. Like that, Silicon Valley spirit I think needs to come to science a little bit more.”
Bhattacharya: Biomedical research is too focused on incremental progress
“I think that's what happened to the culture of biomedical science the last few decades. It's too focused on, like, incremental progress, not enough on enormous.”
Agarwala: Successful VC firms avoid unanimous consensus on bold investments
“It's sort of why many great venture partnerships you know, ourselves included, are not consensus driven. You can't drive, you can't require unanimous consent to fund a big, bold idea, because someone's gonna say, hey, no, no way that's gonna work.”
Bhattacharya: Patient activism forced NIH to address 1980s HIV epidemic
“The early rise in HIV did not, was not met with a sufficient response by the NIH. We're talking very, very early in the early eighties of money going to research on this vital topic. And it was the political movement of HIV patients coming together saying, loo…”
Bhattacharya: Scientists cannot reliably predict which research bets succeed
“Scientists, if you ask us, we're not actually good at predicting the future of the, of future in terms of, like, our will this investment result in productivity? I mean, actually, frankly, neither is Silicon Valley, right? You can't say, you can't promise me t…”
Bhattacharya: US life expectancy hasn't grown in 15 years
“The United States has seen no increase in life expectancy.”
Bhattacharya: Median age of first-time NIH grant recipients rose to mid-40s
“So, in the data out of the NIH is that from, in the 19 eighties, If you were 35, you actually had a chance of getting a large NIH grant. Like, that was the median age of the first large NIH grant, you were 35 years old. Now you're in your mid-forties.”
Bhattacharya: Nobel winners' scientific ideas age half as fast as average researchers'
“So I did a study a few years back where I looked at it turns out that the age of the ideas in your published work ages by every, by one year for every year of chronological age. So my ideas get one year older every year that I age. The very best scientists fig…”
Bhattacharya: NIH will evaluate institute directors on portfolio outcomes, not individual grants
“So what I've done is I've asked the institute directors. I've given them the authority essentially to expand what they can do in terms of the portfolio. I'm not going to judge them to make, just like within Silicon Valley, I'm not going to judge them to s on t…”
Bhattacharya: NIH will judge senior researchers' grant applications on mentorship quality
“And I'm gonna start to evaluate Long established investigators, because I think, I do believe they play a pretty fundamental role still but in the, in, in, in, like, how well do they advance the careers of the early career investigators that work with them, ri…”
Bhattacharya: Transitioning to assistant professor is biomedicine's main bottleneck
“I think the RAID problem isn't that that support for the early, I think we have a lot of portfolios pretty good on that. We could do better, but that's pretty good. The problem is, like, after you've had this career in biomedicine, how do you, like, do you, of…”
Bhattacharya: NIH must reward universities that transition postdocs into professors
“I think we have to do better at that, and we have to reward universities that are better at that.”
Bhattacharya: MAHA movement is a call for NIH reform
“The Maha Movement is a, it's basically a cry for help from the American people, saying, look, all these crime and disease problems, all these problems with our kids, and we're sick, we're much, doing much worse than folks in, in Europe in terms of our health, …”
Bhattacharya: NIH researchers no longer need supervisory approval to publish papers
“I found out that a lot of folks at the internal investigators at the NIH, in order to publish their work, had to seek permission from their supervisors. I changed that. Like, no more permission. You, if you're an NIH researcher, you have a scientific paper, yo…”
Bhattacharya: NIH eliminated paywalls for taxpayer-funded scientific research articles
“They want, they actually had a sort of a if you, a policy where if a regular person wanted to go find a scientific article they had to go, there was a paywall where they pay like 50, a hundred dollars. We got rid of that paywall for NIH-funded research.”
Bhattacharya: COVID plexiglass barriers and restaurant masking lacked scientific backing
“You remember the plexiglass that was everywhere? There's still, every time there's see a plexiglass, it makes me, fills me with rage, but that's another story. And there was no science behind that, right? There was the, there was like the, you wear a mask when…”
Bhattacharya: Weak pandemic school closure policies set children back years educationally
“Closing schools, where again, the science was so weak that it, that and now kids are like years behind in their education as a result, and they'll be paying the price for that for years.”
Bhattacharya: NIH will openly admit when evidence for pandemic guidance is lacking
“God forbid there's another pandemic during my watch, and then I'm asked, okay, how should we manage is, is it right to wear a mask or something, right? And I don't, there's no good scientific evidence. I'm gonna just say that.”
Bhattacharya: Scientists destroyed public trust by falsely claiming certainty during COVID
“The problem is that scientists conveyed certainty about things they had no business conveying certainty about, and then changed people's lives for the worse as a result of it during the pandemic.”
Bhattacharya: Disparity in MMR and COVID child vaccination rates reflects evidence strength
“So, the uptake of MMR in this country, the MMR vaccine is like, 95% of American parents vaccinate their kids with MMR. The evidence is, and, I think it's like, 13% of American parents vaccinated their kids for the COVID vaccine. I think that reflects the scien…”
Bhattacharya: Zostavax shingles vaccine reduces Alzheimer's cognitive decline risk by 20-30%
“A colleague of mine at Stanford did, has this like fantastic paper, he published, set of papers he published using an old shingles vaccine. Called Zostavax. He found that in excellent observational studies that it would, that if you had Zostavax, it reduces th…”
Agarwala: HHS deployed enterprise-secure ChatGPT across the entire agency
“HHS rolled out across, you know, agency-wide an enterprise secure version of ChatGPT”
Bhattacharya: NIH is capping grant applications to block AI-generated submissions
“I'm just to put a new policy in place where I'm limiting the number of new public applications you can have, like to, we can have, you know, six a year, six a cycle or something. We have people writing 60 applications. And very clearly AI-generated. And then w…”
NIH Director Bhattacharya intends to shift NIH funding toward ambitious early-career researchers
“I would love to, that the, to make that happen through the sort of the power of the NIH, to allow the Max Perutz of the world, the new ones who are now, ah, ah, sitting there with great ideas, to be able to ha, to, like, try them out and change the world with …”